Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease

Journal of Clinical Lipidology

Volumn 1, Issue 6, 2007, Pages 620-625

  Moore, Andrew ^a   Phan, Binh An P ^a   Challender, Catherine ^a   Williamson, Jayne ^a   Marcovina, Santica ^b   Zhao, Xue Qiao ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Colesevelam; Dyslipidemia; Lipoproteins; Niacin; Statin

Indexed keywords

ATORVASTATIN; COLESEVELAM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CAROTID ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTENDED RELEASE FORMULATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; NUTRITIONAL COUNSELING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

EID: 36749062943     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.09.001     Document Type: Article

References (16)

1. Miller N.E., Thelle D.S., Forde O.H., and Mjos O.D. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1 (1977) 1965-1968
2. Wilson P.W., Abbott R.D., and Castelli W.P. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 8 (1988) 737-741
3. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
4. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278 [Erratum in: Lancet. 2005;366(9494):1358]
5. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504 [Erratum in: N Engl J Med. 2006;354:778]
6. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
7. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 47 (2006) 2130-2139
8. Brown B.G., Stukovsky K.H., and Zhao X.Q. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials [Review]. Curr Opin Lipidol 17 (2006) 631-636
9. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
10. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517 [Erratum in: Circulation. 2004;110:3615. Circulation. 2005;111:e446]
11. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
13. Zhao X.Q., Morse J.S., Dowdy A.A., et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low-density lipoprotein cholesterol (the HDL Atherosclerosis Treatment Study). Am J Cardiol 93 (2004) 307-312
14. McKenney J.M., Jones P.H., Bays H.E., et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 192 (2007) 432-437 Epub 2007 Jan 19
15. Niacin plus statin to prevent vascular events. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct/show/NCT00120289. 2006.
16. Zhao X.Q., Phan B.A., Chu B., et al. Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by MRI: study design of carotid plaque composition study. Am Heart J 154 2 (2007) 239-246